Kekoolani S. Visan on Muck Rack

Kekoolani S. Visan

As seen in: Nature, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kekoolani S.

Contact Kekoolani S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature

|
By Richard Lobb, Quan Zhou, David Fielding, Kekoolani S. Visan, Alain Wuethrich, Jing Wang, Emma Norris, Sarah Everitt, Lauren G. Aoude, Vanessa F. Bonazzi, Elizabeth Nixon, Jennifer Mooi, Kevin Koo, Kenneth J O'Byrne, Arutha Kulasinghe, Rayleen V Bowman, Ian A Yang, Niall M. Corcoran, Christopher M. Hovens, Michael M MacManus, Jeffrey Gorman, Gunter Hartel, David Whiteman, Niall C Tebbutt, John M. Mariadason, Kwun M. Fong, Andrew Barbour, Matt Trau, Andreas Möller, Youran Hu, Marcus L. Hastie, Brielle Parris
| Cell Reports Medicine Verified
ArticleOnline now102694Open access Affiliations & Notes 1Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia 2Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia 3Department of Thoracic Medicine, Royal Brisbane and Women’s Hospital, Brisbane, QLD 4029, Australia 4JC STEM Lab, Department of Otorhinolaryngology, Chinese University of Hong Kong, Shatin, Hong Kong...
Open in Who Shared Issue with article?

An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer - Communications Biology

|
By Kekoolani S. Visan, Li-Ying Wu
| Nature Verified
Abstract Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide1. Non-small cell lung cancer (NSCLC) patients have a very poor overall five-year survival rate of only 10–20%. Currently, TNM staging is the gold standard for predicting overall survival and selecting optimal initial treatment options for NSCLC patients, including those with curable stages of disease.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified